BACKGROUND: We examined the ability of inhibitors of the synthesis or actions of 20-HETE, metabolite of arachidonic acid, to inhibit proliferation of human renal carcinoma cell lines. MATERIALS AND METHODS: 786-O and 769-P cells were exposed to either 10 microM HET0016 (selective inhibitor of 20-HETE synthesis), 10 microM WIT002 (20-HETE antagonist), or vehicle. Subsequently, we assessed the effect of WIT002 on tumor growth in vivo using an ectopic mouse model of clear-cell renal carcinoma. RESULTS: Addition of HET0016 and WIT002 inhibited the proliferation of 786-O and 769-P human renal cell carcinoma lines. HET0016 and WIT002 had little effect on the proliferation of primary cultures of normal human proximal tubule epithelial cells. WIT002 (10 mg/kg, s.c.) administered daily to athymic nude mice implanted subcutaneously with 786-O cells reduced the growth of the tumors by 84 % compared to vehicle (p<0.001). CONCLUSION: 20-HETE is required for proliferation of human renal epithelial cancer.
BACKGROUND: We examined the ability of inhibitors of the synthesis or actions of 20-HETE, metabolite of arachidonic acid, to inhibit proliferation of humanrenal carcinoma cell lines. MATERIALS AND METHODS: 786-O and 769-P cells were exposed to either 10 microM HET0016 (selective inhibitor of 20-HETE synthesis), 10 microM WIT002 (20-HETE antagonist), or vehicle. Subsequently, we assessed the effect of WIT002 on tumor growth in vivo using an ectopic mouse model of clear-cell renal carcinoma. RESULTS: Addition of HET0016 and WIT002 inhibited the proliferation of 786-O and 769-P humanrenal cell carcinoma lines. HET0016 and WIT002 had little effect on the proliferation of primary cultures of normal human proximal tubule epithelial cells. WIT002 (10 mg/kg, s.c.) administered daily to athymic nude mice implanted subcutaneously with 786-O cells reduced the growth of the tumors by 84 % compared to vehicle (p<0.001). CONCLUSION:20-HETE is required for proliferation of humanrenal epithelial cancer.
Authors: Meng Guo; Richard J Roman; John R Falck; Paul A Edwards; A Guillermo Scicli Journal: J Pharmacol Exp Ther Date: 2005-08-04 Impact factor: 4.030
Authors: C Chao; E Goluszko; Y-T Lee; A A Kolokoltsov; R A Davey; T Uchida; C M Townsend; M R Hellmich Journal: Oncogene Date: 2006-08-14 Impact factor: 9.867
Authors: Meng Guo; Richard J Roman; Joseph D Fenstermacher; Stephen L Brown; John R Falck; Ali S Arbab; Paul A Edwards; A Guillermo Scicli Journal: J Pharmacol Exp Ther Date: 2005-12-13 Impact factor: 4.030
Authors: Austin M Guo; Ju Sheng; Gloria M Scicli; Ali S Arbab; Norman L Lehman; Paul A Edwards; John R Falck; Richard J Roman; A Guillermo Scicli Journal: J Pharmacol Exp Ther Date: 2008-06-30 Impact factor: 4.030
Authors: Wei Yu; Li Chen; Yu-Qing Yang; John R Falck; Austin M Guo; Ying Li; Jing Yang Journal: Cancer Chemother Pharmacol Date: 2010-12-01 Impact factor: 3.333